ARTICLE | Company News
Avecia, Insmed, Tercica metabolic news
May 30, 2005 7:00 AM UTC
The U.K.'s High Court of Justice denied motions made by INSM and Avecia seeking summary judgment in TRCA's patent litigation. TRCA is alleging that its IP is infringed by INSM's SomatoKine diabetes compound. INSM alleges that TRCA's patent should be revoked. TRCA has worldwide rights to IP covering recombinant IGF-1 and IGF-1/IGFBP-3 from Genentech Inc. (DNA, South San Francisco, Calif.). ...